Adicet Announces Promotion of Blake Aftab, Ph.D. to Chief Scientific Officer
12 oct. 2021 16h10 HE
|
Adicet Bio
MENLO PARK, Calif. and BOSTON, Oct. 12, 2021 (GLOBE NEWSWIRE) -- Adicet Bio, Inc. (Nasdaq: ACET), a biotechnology company discovering and developing first-in-class allogeneic gamma delta T cell...
Adicet to Present Preclinical Data from Allogeneic Gamma Delta T Cell Platform at SITC 36th Annual Meeting
04 oct. 2021 07h00 HE
|
Adicet Bio
MENLO PARK, Calif. and BOSTON, Oct. 04, 2021 (GLOBE NEWSWIRE) -- Adicet Bio, Inc. (Nasdaq: ACET), a biotechnology company discovering and developing first-in-class allogeneic gamma delta T cell...
Adicet Bio Collaborates with Twist Bioscience to Accelerate Discovery of Gamma Delta T Cell Cancer Therapeutics
13 sept. 2021 08h00 HE
|
Adicet Bio
MENLO PARK, Calif., and BOSTON, MA, and SOUTH SAN FRANCISCO, Calif., Sept. 13, 2021 (GLOBE NEWSWIRE) -- Adicet Bio, Inc. (Nasdaq: ACET), a biotechnology company discovering and developing...
Adicet Bio to Participate in Upcoming Investor Conferences
02 sept. 2021 16h53 HE
|
Adicet Bio
MENLO PARK, Calif. and BOSTON, Sept. 02, 2021 (GLOBE NEWSWIRE) -- Adicet Bio, Inc. (Nasdaq: ACET), a biotechnology company discovering and developing allogeneic gamma delta T cell therapies for...
Adicet Reports Second Quarter 2021 Financial Results and Provides Business Updates
12 août 2021 16h01 HE
|
Adicet Bio
MENLO PARK, Calif. and BOSTON, Aug. 12, 2021 (GLOBE NEWSWIRE) -- Adicet Bio, Inc. (Nasdaq: ACET), a biotechnology company discovering and developing first-in-class allogeneic gamma delta T cell...
Adicet Bio to Participate in Upcoming Investor Conferences
02 août 2021 07h00 HE
|
Adicet Bio
MENLO PARK, Calif., Aug. 02, 2021 (GLOBE NEWSWIRE) -- Adicet Bio, Inc. (Nasdaq: ACET), a biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other...
Adicet Bio Announces Formation of Scientific Advisory Board
15 juil. 2021 07h00 HE
|
Adicet Bio
MENLO PARK, Calif and BOSTON, July 15, 2021 (GLOBE NEWSWIRE) -- Adicet Bio, Inc. (Nasdaq: ACET), a biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer...
Adicet Bio Added to the Russell 2000® Index
28 juin 2021 07h00 HE
|
Adicet Bio
MENLO PARK, Calif. and BOSTON, June 28, 2021 (GLOBE NEWSWIRE) -- Adicet Bio, Inc. (Nasdaq: ACET), a biotechnology company discovering and developing allogeneic gamma delta T cell therapies for...
Adicet Bio to Participate in Upcoming Investor Conferences
18 mai 2021 16h10 HE
|
Adicet Bio
MENLO PARK, Calif., May 18, 2021 (GLOBE NEWSWIRE) -- Adicet Bio, Inc. (Nasdaq: ACET), a biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other...
Adicet Reports First Quarter 2021 Financial Results and Provides Business Updates
17 mai 2021 07h01 HE
|
Adicet Bio
Initiated Phase 1 Trial of ADI-001 for the Treatment of B Cell Non-Hodgkin's Lymphoma (NHL), interim clinical data expected in late 2021 Successfully raised $143.8 million in net proceeds through a...